自2019年以来,ADC(antibody-drug conjugate,抗体药物偶联物)药物开始崭露头角,并逐步登上了抗肿瘤药物的主流舞台,得到大家广泛的关注,目前已经用于尿路上皮癌(urothelial carcinoma,UC)的治疗。本期由北京大学第一医院何志嵩教授分享晚期尿路上皮癌的治疗现状以及精准靶向治疗的研究进展情况。欢迎关注!
1、化疗
2、免疫治疗
3、ADC治疗药物
向上滑动阅览 【参考文献】 [1] Von der MH, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer [J]. J Clin Oncol, 2005,23(21):4602-4608. [2] Bellmunt J, Maase H, Mead GM, et al. Randomized phase Ⅲ study comparing paclitaxel/cisplatin/ gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: Eortc intergroup study 30987 [J]. J Clin Oncol, 2012,30(10):1107-1113. [3]Fradet Y, et al. Ann Oncol. 2019 Jun 1;30(6):970-976. [4] Tagawa ST, Balar AV, Petrylak DP, et al. TROPHY-U-01: a phaseⅡopen-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors[J]. J Clin Oncol, 2021, 39(22):2474-2485. [5] J Alfred Ws, Thierry L, Eva MC, et al. Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer[J]. European Urology, 2017, 71(3) : 462-475. [6] Von der MH, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study.[J]. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 2000, 18(17) : 3068-77. [7] JT Roberts, H von der Maase, L Sengeløv, et al. Long-term survival results of a randomized trial comparing gemcitabine/cisplatin and methotrexate/vinblastine/doxorubicin/cisplatin in patients with locally advanced and metastatic bladder cancer[J]. Annals of Oncology, 2006, 17(Supl.5) : v118-v122. [8] O'Donnell PH, Arkenau HT, Sridhar SS, et al. Patient-reported outcomes (PROs) in patients with urothelial carcinoma (UC) treated with durvalumab (second-line or above) in phase 1/2 dose-escalation study 1108.[J]. Journal of Clinical Oncology, 2018, 36(15_suppl): 4532-4532. [9] De SM, Bellmunt J, Mead G, et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol. 2012 Jan 10;30(2):191-9. [10] Kim HS, Seo HK. Immune checkpoint inhibitors for urothelial carcinoma. Investig Clin Urol. 2018 Sep;59(5):285-296. [11] Bardia A, Messersmith WA, Kio EA, Berlin JD, Vahdat L, Masters GA, Moroose R, Santin AD, Kalinsky K, Picozzi V, O'Shaughnessy J, Gray JE, Komiya T, Lang JM, Chang JC, Starodub A, Goldenberg DM, Sharkey RM, Maliakal P, Hong Q, Wegener WA, Goswami T, Ocean AJ. Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial. Ann Oncol. 2021 Jun;32(6):746-756. [12] Powles Thomas, Jonathan ER, Guru PS, et al. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma[J]. New England Journal of Medicine, 2021, 384(12): 1125-1135. 声明:本内容仅代表嘉宾观点,不代表学习联盟平台立场。本内容仅供医学药学专业人士阅读,不构成实际治疗建议。 编辑:王靖 审核:王冬 |
|